tetano
Editor, Senior Moderator
Front Immunol
. 2022 Sep 2;13:975363.
doi: 10.3389/fimmu.2022.975363. eCollection 2022.
COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
Jung Yeon Heo[SUP] 1 [/SUP], Yu Bin Seo[SUP] 2 [/SUP], Eun Jin Kim[SUP] 1 [/SUP], Jacob Lee[SUP] 2 [/SUP], Young Rong Kim[SUP] 1 [/SUP], Jin Gu Yoon[SUP] 3 [/SUP], Ji Yun Noh[SUP] 3 4 5 [/SUP], Hee Jin Cheong[SUP] 3 4 5 [/SUP], Woo Joo Kim[SUP] 3 4 5 [/SUP], Soo-Young Yoon[SUP] 6 [/SUP], Ju-Yeon Choi[SUP] 7 [/SUP], Young Jae Lee[SUP] 7 [/SUP], Hye Won Lee[SUP] 7 [/SUP], Sung Soon Kim[SUP] 7 [/SUP], Byoungguk Kim[SUP] 7 [/SUP], Joon Young Song[SUP] 3 4 5 [/SUP]
Affiliations
Abstract
Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood samples before and after sequential two-dose vaccinations of BNT162b2 and ChAdOx1 nCoV-19. Outcomes included anti-S IgG antibody and neutralizing antibody responses, adverse events, and proinflammatory cytokine responses. A total of 59 and 57 participants vaccinated with BNT162b2 and ChAdOx1 nCoV-19, respectively, were enrolled. Systemic adverse events were more common after the first ChAdOx1 nCoV-19 dose than after the second. An opposite trend was observed in BNT162b2 recipients. Although the first ChAdOx1 nCoV-19 dose significantly elevated the median proinflammatory cytokine levels, the second dose did not, and neither did either dose of BNT162b2. Grades of systemic adverse events in ChAdOx1 nCoV-19 recipients were significantly associated with IL-6 and IL-1β levels. Anti-S IgG and neutralizing antibody titers resulting from the second BNT162b2 dose were significantly associated with fever. In conclusion, systemic adverse events resulting from the first ChAdOx1 nCoV-19 dose may be associated with proinflammatory cytokine responses rather than humoral immune responses. Febrile reactions after second BNT162b2 dose were positively correlated with vaccine-induced immune responses rather than with inflammatory responses.
Keywords: COVID-19; cytokine; immunogenicity; reactogenicity; vaccine.
. 2022 Sep 2;13:975363.
doi: 10.3389/fimmu.2022.975363. eCollection 2022.
COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19
Jung Yeon Heo[SUP] 1 [/SUP], Yu Bin Seo[SUP] 2 [/SUP], Eun Jin Kim[SUP] 1 [/SUP], Jacob Lee[SUP] 2 [/SUP], Young Rong Kim[SUP] 1 [/SUP], Jin Gu Yoon[SUP] 3 [/SUP], Ji Yun Noh[SUP] 3 4 5 [/SUP], Hee Jin Cheong[SUP] 3 4 5 [/SUP], Woo Joo Kim[SUP] 3 4 5 [/SUP], Soo-Young Yoon[SUP] 6 [/SUP], Ju-Yeon Choi[SUP] 7 [/SUP], Young Jae Lee[SUP] 7 [/SUP], Hye Won Lee[SUP] 7 [/SUP], Sung Soon Kim[SUP] 7 [/SUP], Byoungguk Kim[SUP] 7 [/SUP], Joon Young Song[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 36119092
- PMCID: PMC9480614
- DOI: 10.3389/fimmu.2022.975363
Abstract
Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines. Here, we evaluated the association between reactogenicity and immunogenicity in healthy adults following vaccination by analyzing blood samples before and after sequential two-dose vaccinations of BNT162b2 and ChAdOx1 nCoV-19. Outcomes included anti-S IgG antibody and neutralizing antibody responses, adverse events, and proinflammatory cytokine responses. A total of 59 and 57 participants vaccinated with BNT162b2 and ChAdOx1 nCoV-19, respectively, were enrolled. Systemic adverse events were more common after the first ChAdOx1 nCoV-19 dose than after the second. An opposite trend was observed in BNT162b2 recipients. Although the first ChAdOx1 nCoV-19 dose significantly elevated the median proinflammatory cytokine levels, the second dose did not, and neither did either dose of BNT162b2. Grades of systemic adverse events in ChAdOx1 nCoV-19 recipients were significantly associated with IL-6 and IL-1β levels. Anti-S IgG and neutralizing antibody titers resulting from the second BNT162b2 dose were significantly associated with fever. In conclusion, systemic adverse events resulting from the first ChAdOx1 nCoV-19 dose may be associated with proinflammatory cytokine responses rather than humoral immune responses. Febrile reactions after second BNT162b2 dose were positively correlated with vaccine-induced immune responses rather than with inflammatory responses.
Keywords: COVID-19; cytokine; immunogenicity; reactogenicity; vaccine.